Our funding in numbers.
The Boehringer Ingelheim Foundation fulfils its statutory purpose by funding excellent basic research in medicine, biology, chemistry, and pharmacy. Its funding focus lies on the University of Mainz.
The Foundation’s Germany-wide Plus 3 and Exploration Grants programmes offer outstanding and independent junior group leaders the freedom necessary to realise their scientific potential and to test new ideas. The Foundation also supports scientific conferences around the world, with the particular aim of promoting dialogue between different generations of scientists.
The Foundation awards the internationally renowned Heinrich Wieland Prize to honour distinguished scientists from around the world for their ground-breaking research.It also endows awards for excellent junior researchers, namely the Boehringer Ingelheim Prize and four PhD student prizes at the University of Mainz.
As a recognised charitable organisation, the Boehringer Ingelheim Foundation is not subject to corporate and trade taxes (current notice of tax exemption issued by the Bingen-Alzey tax office in May 2016, for 2012 to 2014, tax ID number 08/667/10470).
Funds approved in 2017
In 2017 alone, the Boehringer Ingelheim Foundation approved more than 17 million euros in funding. About 30 per cent of this was granted within the Plus 3 and Exploration Grants programmes, for scientific conferences, and scientific awards. In addition, the Foundation extended the funding of the International PhD Programme (IPP) in Mainz and decided to support two new initiatives: the EMBL Imaging Technology Centre in Heidelberg for 10 years, and the German Resilience Center in Mainz for 3 years.
In addition, in 2017, the Foundation paid out grants for initiatives and projects decided upon in previous years. Among the beneficiaries of these grants were the Institute of Molecular Biology (IMB), the Faculty of Biology at the University of Mainz, the International PhD Programme (IPP) in Mainz, a cardiovascular research consortium at University Medical Center Mainz, and various projects within the Plus 3 and Exploration Grants programmes. The BIS also funded the Boehringer Ingelheim Fonds, Foundation for Basic Research in Medicine (BIF).